Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial

Primary Objective

This is a double-blind, placebo-controlled, parallel group study designed to assess the tolerability and efficacy of fsCBD and bsCBD, compared to a placebo control, to improve cognition and traumatic brain injury-related symptoms. If eligible for the study, subjects will be randomized to receive one of the conditions for 12 weeks.

Is this Study for You?

Let's Get Started!


Our study is seeking individuals aged 18-60, who have been diagnosed with a traumatic brain injury (TBI) to participate. The study plans to learn more about the impacts of cannabidiol (CBD) on individuals with TBI. The 12-weeks of the study will involve using CBD or placebo.

Main Procedures Involved: -Blood draw -Questionnaires and cognitive tasks -Urine drug test

Duration of Participation: 12 weeks


18 to 60 years


-Between the ages of 18-60 -Diagnosed with a traumatic brain injury (TBI) -Interested in using cannabidiol (CBD) for TBI symptoms

Type of Study






Principal Investigator
Photograph of Kent Hutchison,  PhD

Kent Hutchison, PhD

Study ID

Protocol Number: 22-1427

More information available at NCT05632627

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers